Muscular dystrophy is a group of genetic diseases characterized by progressive muscle degeneration. Working with mice with a type of the disease, researchers have found that by expressing an enzyme ...

Spinal muscular atrophy (SMA) is a genetic neuromuscular condition caused by mutations in the SMN1 gene. SMA is characterized by symmetrical progressive (proximal predominant) muscle atrophy caused by ...

Boys with Duchenne Muscular Dystrophy will usually lose the ability to walk by their teens and typically die before the age of 30. For years, scientists have studied the use of gene therapy as a ...

Muscular dystrophy is a group of rare muscle-wasting diseases with a wide range of biological features, symptoms, and genetic origins. To obtain a precise diagnosis and offer appropriate genetic ...

Muscular Dystrophies are a group of genetic conditions characterized by muscle weaknesses. They are genetic conditions and have different sub-categories depending on which area of muscle mass is ...

Please provide your email address to receive an email when new articles are posted on . BridgeBio Pharma Inc. announced it has received FDA fast track designation for BBP-418 as a treatment option for ...

Muscles play a part in every function of the body. The muscular system is made up of over 600 muscles. These include three muscle types: smooth, skeletal, and cardiac. Only skeletal muscles are ...

Durham-based Precision BioSciences, a gene-editing company, has received regulatory clearance to begin a clinical study of its potential treatment for Duchenne muscular dystrophy (DMD), a rare ...

EVRY, France--(BUSINESS WIRE)--Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting muscular dystrophies and cardiomyopathies, today ...

PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced ...